Resveratrol counteracts IL‐1β‐mediated impairment of extracellular matrix deposition in 3D articular chondrocyte constructs
Open Access
- 17 March 2020
- journal article
- research article
- Published by Wiley in Journal of Tissue Engineering and Regenerative Medicine
- Vol. 14 (7) , 897-908
Abstract
When aiming at cell‐based therapies in osteoarthritis (OA), pro‐inflammatory conditions mediated by cytokines such as IL‐1β need to be considered. In recent studies, the phytoalexin resveratrol (RSV) has exhibited potent anti‐inflammatory properties. However, long‐term effects on 3D cartilaginous constructs under inflammatory conditions with regard to tissue quality, especially extracellular matrix (ECM) composition, have remained unexplored. Therefore, we employed long‐term model cultures for cell‐based therapies in an in vitro OA environment and evaluated effects of RSV. Pellet constructs made from expanded porcine articular chondrocytes were cultured with either IL‐1β (1‐10 ng/ml) or RSV (50 μM) alone, or a co‐treatment with both agents. Treatments were applied for 14 days, either directly after pellet formation or after a preculture period of 7 days. Culture with IL‐1β (10 ng/ml) decreased pellet size and DNA amount, and severely compromised glycosaminoglycan (GAG) and collagen content. Co‐treatment with RSV distinctly counteracted the pro‐inflammatory catabolism and led to partial rescue of the ECM composition in both culture systems, with especially strong effects on GAG. Marked MMP13 expression was detected in IL‐1β‐treated pellets, but none upon RSV co‐treatment. Expression of collagen type I was increased upon IL‐1β treatment and still observed when adding RSV, while collagen type X, indicating hypertrophy, was detected exclusively in pellets treated with RSV alone. In conclusion, RSV can counteract IL‐1β‐mediated degradation and distinctly improve cartilaginous ECM deposition in 3D long‐term inflammatory cultures. Nevertheless, potential hypertrophic effects should be taken into account when considering RSV as co‐treatment for articular cartilage repair techniques.Keywords
Funding Information
- FP7 Nanosciences, Nanotechnologies, Materials and new Production Technologies (309962, FP7/2007‐2013)
This publication has 38 references indexed in Scilit:
- TGF‐β1‐Modified Hyaluronic Acid/Poly(glycidol) Hydrogels for Chondrogenic Differentiation of Human Mesenchymal Stromal CellsMacromolecular Bioscience, 2018
- A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the kneeArthritis Research & Therapy, 2011
- Assessment of synovitis with contrast-enhanced MRI using a whole-joint semiquantitative scoring system in people with, or at high risk of, knee osteoarthritis: the MOST studyAnnals of the Rheumatic Diseases, 2011
- Risk factors for onset of osteoarthritis of the knee in older adults: a systematic review and meta-analysisOsteoarthritis and Cartilage, 2010
- Synergistic chondroprotective effects of curcumin and resveratrol in human articular chondrocytes: inhibition of IL-1β-induced NF-κB-mediated inflammation and apoptosisArthritis Research & Therapy, 2009
- ERK1/2 Activation Induced by Inflammatory Cytokines Compromises Effective Host Tissue Integration of Engineered CartilageTissue Engineering Part A, 2009
- The antioxidant resveratrol protects against chondrocyte apoptosis via effects on mitochondrial polarization and ATP productionArthritis & Rheumatism, 2008
- Regulation of inflammation signalling by resveratrol in human chondrocytes in vitroBiochemical Pharmacology, 2008
- Differential Effects of Growth Factors on Tissue-Engineered CartilageTissue Engineering, 2002
- Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blueBiochimica et Biophysica Acta (BBA) - General Subjects, 1986